Gary Novack of PharmaLogic to Speak at 5th Ocular Diseases Conference March 2013

Printer-friendly versionPDF version

Gary Novack, President at PharmaLogic Development To Give a Featured Presentation at the 5th Ocular Diseases & Drug Development Conference (March 21-22, 2013 in San Francisco, CA)

San Francisco,  CA, USA., January 10, 2013 - (PressReleasePoint) - Gary Novack, President at PharmaLogic Development will give a featured presentation on “Thirty Years of Developing New Therapeutic Ophthalmic Drugs – Some Simple Principles” at GTC’s 5th Ocular Diseases and Drug Development Conference to be held in San Francisco, CA on March 21-22, 2013.
 
Gary has been involved in the development of scores of ophthalmic products for over 30 years. In his presentation, he will present a brief list of basic principles of pharmacology, the scientific method, and communication and their application to ophthalmic product development. He will also discuss how these product development perspectives align with regulatory laws, regulations and guidances.


Gary D. Novack, Ph.D. is the Founder and President of PharmaLogic Development, Inc.  PharmaLogic is a consultancy providing development expertise to pharmaceutical and medical device companies.  PharmaLogic specializes in ophthalmology and other local therapies.  Dr. Novack studied at the University of California (BA from UC Santa Cruz, PhD in Pharmacology and Toxicology from UC Davis, and postdoctoral fellowship in neurophysiology at UCLA).  He earned his diplomate in clinical pharmacology in 1990, the inaugural year of the certification.  Dr. Novack has served as a Regent of the University of California, President of the UC Santa Cruz Foundation, and President of the UC Santa Cruz Alumni Association.  He has authored over 175 papers, and played a key role in the approval of over 40 ophthalmic products.  
 
GTC’s 5th Ocular Diseases and Drug Development Conference promotes the discovery of ocular disease drug development by bringing together leading scientists, researchers, and experts to discuss and collaborate on the latest research and discovery, safety assessment, and drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other eye diseases. The last annual conference was well attended by key R&D delegates GSK, Pfizer, B&L, Allergan and Alcon, and this year’s conference promises to be even bigger and better.
 
For more information, please visit www.gtcbio.com